TransThera Sciences (Nanjing), Inc. (SEHK: 2617)
Health Care · Biotechnology · CN
HK$10.33
-3.91% today · -80.9% 1Y
TransThera Sciences (Nanjing), Inc. (SEHK: 2617) operates in the Biotechnology industry within the Health Care sector. The company is valued at $536.97M and employs 123 people.
Over the last twelve months the share price has lost 80.9%, trading between 9.01 and 679.50.
Tweenvest scores TransThera Sciences (Nanjing), Inc. across four factors: quality 29/100. Its strongest factor is quality.
2617 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $536.97M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.76
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$679.50
- 52-week low
- HK$9.01
- Avg volume (3M)
- —
- Shares outstanding
- 407.92M
- Employees
- 123
- Next earnings
- —
About TransThera Sciences (Nanjing), Inc.
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.
- ISIN
- CNE100006T02
- Founded
- 2014
- Listed since
- Jun 23, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.80 | +0.00% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $444.00 | +0.40% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €903.40 | +2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.51 | -2.09% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.